Oncology - European Medical Journal

Continue

Oncology

Filter
7 Mins
5 Nov 2020

Nasopharyngeal Rhabdomyosarcoma: A Rare Malignancy Incidentally Found in a Middle-Aged Male with a Diagnostic Dilemma

Rhabdomyosarcoma (RMS) is an infrequent and aggressive malignancy that emerges from embryonic mesenchymal cells…
10 Mins
21 Sep 2020

Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update

Urothelial cancer is the 9th most common cancer in the world and the 10th most common cancer in the UK…
7 Mins
17 Sep 2020

Editor's Pick: Tumour-Associated Hypoxia: Can We Give Chimeric Antigen Receptor T Cells More Breathing Space?

Chimeric antigen receptors (CAR) are fusion molecules that couple the binding of a native tumour-associated target to the delivery of a bespoke T…
9 Mins
17 Sep 2020

Metastasis: A Bane of Breast Cancer Therapy

Breast cancer is one of the most commonly diagnosed cancers among women.1 Despite advances in treatment for breast cancer…
12 Mins
17 Sep 2020

Putting into Perspective the Future of Cancer Vaccines: Targeted Immunotherapy

Cancer is a genetic and epigenetic disease of multicellularity, driving transformed cells to uncontrolled growth, invasion, and metastasis. In cancer, intracellular mechanisms controlling cellular proliferation are damaged first, which allows certain cells to progress to malignant transformation…
14 Mins
10 Sep 2020

Unmet Medical Need in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutations: A Review

Colorectal cancer (CRC) is the most common gastrointestinal malignancy. Worldwide, it is the second most common cancer in females…
EMJ Oncology 8 [Supplement 2] 2020
8 Mins
26 Aug 2020

Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer

MONARCH 2 was a global, randomised, double-blind, Phase III study of abemaciclib or placebo in combination with fulvestrant in premenopausal…
EMJ Oncology 8 [Supplement 2] 2020
14 Mins
26 Aug 2020

Latest Developments in Advanced Breast Cancer Treatment: A Discussion with Two Key Opinion Leaders about the CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib

The introduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of advanced breast cancer (ABC; inoperable locally advanced…